drugset / Trial / NCT00589381

Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma

NCT00589381

Non-randomizedOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as fenretinide Lym-X-Sorb™ , work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide Lym-X-Sorb™ in treating patients with recurrent or resistant solid tumors or lymphoma.

Timeline

Start
2007-08
Primary completion
2010-12
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject fenretinide Small molecule 800 mg/m2 Oral
Subject fenretinide Small molecule 1000 mg/m2 Oral